In a preclinical study, tumor-reactive CD8+ T cells were isolated from RCC patients, activated with autologous immature DCs and tumor lysate, and infected with a TβRIIDN retrovirus to inhibit TGFβ signaling. This evidence concerns the gene CD8A and renal cell carcinoma.